We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$9.89B
$155M 9.14%
1,394,019
+76,690
+6% +$9.08M
PTGX icon
2
Protagonist Therapeutics
PTGX
$9.34B
$105M 6.17%
994,119
-55,049
-5% -$4.87M
ROIV icon
3
Roivant Sciences
ROIV
$25.1B
$91M 5.36%
3,285,906
-143,056
-4% -$3.67M
IMVT icon
4
Immunovant
IMVT
$8.51B
$66.5M 3.92%
2,679,010
+198,042
+8% +$5.13M
SPY icon
5
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$49.4M 2.91%
75,940
+21,256
+39% +$14.5M
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
$48.2M 2.84%
914,699
+373,084
+69% +$15.3M
CYTK icon
7
Cytokinetics
CYTK
$10B
$41.7M 2.45%
632,556
+92,390
+17% +$5.87M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$9B
$41.4M 2.44%
1,139,331
+829,963
+268% +$37.1M
BOXX icon
9
Alpha Architect 1-3 Month Box ETF
BOXX
$14B
$39.2M 2.31%
337,125
– –
DNLI icon
10
Denali Therapeutics
DNLI
$3.84B
$35.9M 2.12%
1,871,455
+1,819,339
+3,491% +$36.2M
BEAM icon
11
Beam Therapeutics
BEAM
$3.03B
$34.5M 2.03%
+1,446,375
New +$40.1M
ZLAB icon
12
Zai Lab
ZLAB
$2.93B
$26.8M 1.58%
1,425,367
+178,847
+14% +$3.31M
SEPN
13
Septerna Inc
SEPN
$1.82B
$26.2M 1.54%
1,089,818
-67,793
-6% -$1.78M
VIR icon
14
Vir Biotechnology
VIR
$1.83B
$24.6M 1.45%
+2,744,714
New +$21.9M
DBVT
15
DBV Technologies
DBVT
$851M
$21.2M 1.25%
+1,012,866
New +$21.2M
AVR
16
Anteris Technologies
AVR
$852M
$21M 1.24%
3,789,132
+2,550,355
+206% +$14.7M
INSP icon
17
Inspire Medical Systems
INSP
$1.78B
$20.9M 1.23%
405,197
+390,197
+2,601% +$27.3M
SRRK icon
18
Scholar Rock
SRRK
$7.04B
$20M 1.18%
407,273
+337,684
+485% +$15.1M
RYTM icon
19
Rhythm Pharmaceuticals
RYTM
$7.38B
$18.4M 1.08%
211,450
+160,101
+312% +$15.6M
SYRE icon
20
Spyre Therapeutics
SYRE
$7.97B
$17.1M 1%
338,323
+304,272
+894% +$11.5M
CTMX icon
21
CytomX Therapeutics
CTMX
$699M
$16M 0.94%
3,410,190
-772,579
-18% -$3.92M
PRTA icon
22
Prothena Corp
PRTA
$479M
$15.4M 0.9%
1,581,443
+123,679
+8% +$1.13M
SNY icon
23
Sanofi
SNY
$107B
$15.3M 0.9%
316,939
+253,465
+399% +$11.8M
PCVX icon
24
Vaxcyte
PCVX
$8.9B
$15.1M 0.89%
259,137
-56,505
-18% -$3.07M
MNPR icon
25
Monopar Therapeutics
MNPR
$751M
$14.5M 0.85%
264,278
+30,370
+13% +$1.83M
1
2 3 4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.